Does Wellcare Cover Wegovy?

No. Medicare Part D cannot cover any drug for weight loss; this is a federal statute that applies to all Medicare plans, including every Wellcare Part D plan. Starting July 1, 2026, the Medicare GLP-1 Bridge gives eligible Wellcare beneficiaries access to Wegovy for weight loss at $50 per month outside Part D through December 31, 2027. If you have established cardiovascular disease, the CV indication is a separate coverage path under Part D that predates the Bridge.

Wellcare is a participating plan in the Medicare GLP-1 Bridge program, which launches July 1, 2026. Eligible beneficiaries pay a fixed $50 per month copay for Wegovy weight-loss access. The Bridge operates outside Part D, so the $50 doesn't count toward your deductible, TrOOP, or the $2,100 OOP cap, and Extra Help can't be applied. Eligibility requires provider attestation of qualifying BMI criteria, and members already on a Part D-covered GLP-1, such as Ozempic for diabetes, aren't eligible. Humana, not Wellcare, administers the Bridge as CMS's central processor.

Both Humana and Wellcare are Medicare-first plans where the Part D statutory exclusion and Bridge are the operative story. The key distinction is that Humana is the CMS-selected central processor for the entire Medicare GLP-1 Bridge program, giving the Humana page program-administration authority. Wellcare is a participating plan in the Bridge, not its administrator. Both pages cover the same Medicare coverage logic, but Humana's role in running the Bridge is a unique operational fact that doesn't apply to Wellcare.

Only in states whose Medicaid program covers GLP-1s for obesity, 13 states as of January 2026. Wellcare operates Medicaid managed-care plans across multiple states. Whether your specific state's Medicaid program covers Wegovy for obesity is a state-government decision, not a Wellcare decision. Verify on your state-specific Wellcare Medicaid formulary. The cardiovascular indication is covered across states for qualifying members.

No. The NovoCare Wegovy Savings Offer is not available to Medicare or Medicaid beneficiaries due to federal anti-kickback rules. Because Wellcare's membership is predominantly Medicare Part D and Medicaid, the savings card is generally not applicable. Commercially insured Wellcare members whose plan covers Wegovy may be eligible; verify at novocare.com.

Two significant pricing changes take effect January 1, 2027. Novo Nordisk has announced it will reduce Wegovy's list price to approximately $675 per month. The IRA-negotiated Maximum Fair Price for semaglutide of $274 per 30-day supply also takes effect for Medicare. For Wellcare Medicare beneficiaries, this may meaningfully reduce out-of-pocket costs for the CV indication after the $2,100 cap is reached. The Medicare Bridge's $50 per month copay and its terms through December 2027 remain as currently announced.

Ozempic is FDA-approved for type 2 diabetes, not weight loss, so it's handled differently from Wegovy under Wellcare's Medicare Part D plans. Members with a documented diabetes diagnosis can have Ozempic covered under Part D for that indication, subject to your specific plan's formulary and tier placement. Using Ozempic off-label for weight loss isn't covered through that diabetes pathway, and having an existing Part D-covered GLP-1 like Ozempic actually makes you ineligible for the separate Medicare GLP-1 Bridge for Wegovy.

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes and, like Ozempic, can potentially be covered under Wellcare's Medicare Part D for that diagnosis, subject to your plan's formulary. Zepbound is the same drug, tirzepatide, branded for weight loss, which puts it under the same federal Part D weight-loss exclusion that applies to Wegovy. Whether Zepbound is included in the Medicare GLP-1 Bridge program for your plan isn't something this page confirms, so verify directly with Wellcare or check the Bridge program's current drug list.

Value Script is one of Wellcare's specific Medicare Part D plan offerings, but it's still a Part D plan, so the same federal rule applies: Part D cannot cover Wegovy for weight loss regardless of which specific Wellcare plan name you have. The cardiovascular risk reduction indication and the separate Medicare GLP-1 Bridge program for weight loss both remain available the same way they are for other Wellcare Part D plans. Check your Value Script plan's specific drug list for tier placement and prior authorization details on the CV indication.

Wellcare publishes a plan-specific drug list, often called a formulary, for each of its Medicare and Medicaid plans, typically available as a searchable tool or downloadable PDF on the Wellcare member portal or website. Because Wellcare offers multiple plan types and names, including Value Script, the exact drug list you need depends on your specific plan, so log in with your member ID or call Wellcare member services to pull the right one.